Basic Information
RNALocate ID: | RLID:11001038 |
RNA Symbol: | hsa-miR-106a-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-106a-5p |
RNA ID: | miRBase:MIMAT0000103 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 22211110 |
Tissue/Cell Line: | Breast milk |
Method: | Next-generation RNA sequencing |
The expression profile of selected miRNAs in breast milk exosomes. Originally published in Int J Biol Sci. Zhou Q, et al, 2012. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | Distribution and characterization of miRNAs in breast milk exosomes. (A) Distribution of pre-miRNAs. Out of 1,424 pre-miRNAs deposited in miRBase 17.0 (blue circle), 87 (6.11%) pre-miRNAs have been designated as immune-related pre-miRNAs based on annotation in the Pathway Central database (SABiosciences, MD, USA). Immune-related pre-miRNAs (59 of 452, 13.05%) are enriched in breast milk exosomes (red circle). χ2 test: Number of immune-related miRNAs and others detected in breast milk exosomes compared with the total entries in miRBase 17.0. (B) Top ten most highly expressed unique miRNAs. Plot of the unique miRNAs (starting from the miRNA with the highest counts, x-axis) versus their cumulative % of the total counts from 602 unique miRNAs detected in breast milk exosomes for each small RNA library. Values are means ± s.d. The dashed horizontal line at 62.3% represents the level of the top ten unique miRNAs and the % of individual miRNAs is marked by the gray line. (C-E) The expression profile of selected miRNAs in breast milk exosomes. (C) 59 immune-related pre-miRNAs; (D) miR-17-92 cluster and paralogous clusters, and (E) ten well-characterized tissue-specific pre-miRNAs. Data are collected from Figure 2. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001467 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001468 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01001469 | Cytoplasm | Cell line (HeLa) | 21695135 |
RLID:01001470 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001471 | Mitochondrion | Myotube | 27396686 |
RLID:01001472 | Mitochondrion | Skeletal muscle cells | 27563705 |
RLID:01001473 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001474 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001475 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001476 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001477 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:11001035 | Apoptotic body | Human umbilical vein endothelial cells | 19996457 |
RLID:11001036 | Exosome | Sera | 24978137 |
RLID:11001037 | Exosome | Plasma | 19289371 |
RLID:11001039 | Exosome | Brain tissue | 23382797 |
RLID:11001040 | Exosome | Plasma | 23663360 |
RLID:11001041 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11001042 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11001043 | Exosome | Serum | 25349172 |
RLID:11001044 | Microvesicle | Seminal plasma | 23539611 |
RLID:11001045 | Microvesicle | Follicular fluid | 23666971 |
RLID-D:11000302 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
RLID-D:11001161 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-106a-5p | Diffuse large b cell lymphoma | MNDR-E-MI-03360 |
MNDR | hsa-miR-106a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-03361 |
MNDR | hsa-miR-106a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-03362 |
MNDR | hsa-miR-106a-5p | Oral squamous cell carcinoma | MNDR-E-MI-03363 |
MNDR | hsa-miR-106a-5p | Follicular cleaved lymphoma | MNDR-E-MI-03364 |
MNDR | hsa-miR-106a-5p | Medulloblastoma | MNDR-E-MI-03365 |
MNDR | hsa-miR-106a-5p | Small intestinal neuroendocrine tumor | MNDR-E-MI-03366 |
MNDR | hsa-miR-106a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-03367 |
MNDR | hsa-miR-106a-5p | Ovarian clear cell carcinoma | MNDR-E-MI-03368 |
MNDR | hsa-miR-106a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-03369 |
MNDR | hsa-miR-106a-5p | Lymphoma | MNDR-E-MI-03370 |
MNDR | hsa-miR-106a-5p | Lymphoma non-hodgkin | MNDR-E-MI-03371 |
MNDR | hsa-miR-106a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-03372 |
MNDR | hsa-miR-106a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-03373 |
MNDR | hsa-miR-106a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-03374 |
MNDR | hsa-miR-106a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-03375 |
MNDR | hsa-miR-106a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-03376 |
MNDR | hsa-miR-106a-5p | Breast cancer luminal | MNDR-E-MI-03377 |
MNDR | hsa-miR-106a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-03378 |
MNDR | hsa-miR-106a-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-03379 |
MNDR | hsa-miR-106a-5p | Small intestine cancer | MNDR-E-MI-03380 |
MNDR | hsa-miR-106a-5p | Prostate cancer | MNDR-E-MI-03381 |
MNDR | hsa-miR-106a-5p | Gastric cancer | MNDR-E-MI-03382 |
MNDR | hsa-miR-106a-5p | Gastric lymphoma | MNDR-E-MI-03383 |
MNDR | hsa-miR-106a-5p | Alzheimer disease | MNDR-E-MI-03384 |
MNDR | hsa-miR-106a-5p | Dysautonomia familial | MNDR-E-MI-03385 |
MNDR | hsa-miR-106a-5p | Leukemia | MNDR-E-MI-03386 |
MNDR | hsa-miR-106a-5p | Huntington disease | MNDR-E-MI-03387 |
MNDR | hsa-miR-106a-5p | Chorea | MNDR-E-MI-03388 |
MNDR | hsa-miR-106a-5p | Carotid stenosis | MNDR-E-MI-03389 |
MNDR | hsa-miR-106a-5p | Lung cancer | MNDR-E-MI-03390 |
MNDR | hsa-miR-106a-5p | Fragile x syndrome | MNDR-E-MI-03391 |
MNDR | hsa-miR-106a-5p | Parkinson disease | MNDR-E-MI-03392 |
MNDR | hsa-miR-106a-5p | Basal-like breast cancer | MNDR-E-MI-03393 |
MNDR | hsa-miR-106a-5p | Pancreatic cancer | MNDR-E-MI-03394 |
MNDR | hsa-miR-106a-5p | Melanoma | MNDR-E-MI-03395 |
MNDR | hsa-miR-106a-5p | Lesch-nyhan syndrome | MNDR-E-MI-03396 |
MNDR | hsa-miR-106a-5p | Rectum adenocarcinoma | MNDR-E-MI-03397 |
MNDR | hsa-miR-106a-5p | Hepatitis B | MNDR-E-MI-03398 |
MNDR | hsa-miR-106a-5p | Epithelial ovarian cancer | MNDR-E-MI-03399 |
MNDR | hsa-miR-106a-5p | Nephroblastoma | MNDR-E-MI-03400 |
MNDR | hsa-miR-106a-5p | Colon cancer | MNDR-E-MI-03401 |
MNDR | hsa-miR-106a-5p | Ischemic attack transient | MNDR-E-MI-03402 |
MNDR | hsa-miR-106a-5p | Colon adenocarcinoma | MNDR-E-MI-03403 |
MNDR | hsa-miR-106a-5p | Multiple sclerosis | MNDR-E-MI-03404 |
MNDR | hsa-miR-106a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-03405 |
MNDR | hsa-miR-106a-5p | Familial ovarian cancer | MNDR-E-MI-03406 |
MNDR | hsa-miR-106a-5p | Prostate adenocarcinoma | MNDR-E-MI-03407 |
MNDR | hsa-miR-106a-5p | Kidney cancer | MNDR-E-MI-03408 |
MNDR | hsa-miR-106a-5p | Carcinoma ductal breast | MNDR-E-MI-03409 |
MNDR | hsa-miR-106a-5p | Glioblastoma | MNDR-E-MI-03410 |
MNDR | hsa-miR-106a-5p | Astrocytoma | MNDR-E-MI-03411 |
MNDR | hsa-miR-106a-5p | Glioma | MNDR-E-MI-03412 |
MNDR | hsa-miR-106a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-03413 |
MNDR | hsa-miR-106a-5p | Epilepsy temporal lobe | MNDR-E-MI-03414 |
MNDR | hsa-miR-106a-5p | Osteosarcoma | MNDR-E-MI-03415 |
MNDR | hsa-miR-106a-5p | Liposarcoma | MNDR-E-MI-03416 |
MNDR | hsa-miR-106a-5p | Meningioma | MNDR-E-MI-03417 |
MNDR | hsa-miR-106a-5p | Liver cancer | MNDR-E-MI-03418 |
MNDR | hsa-miR-106a-5p | Cervical adenocarcinoma | MNDR-E-MI-03419 |
MNDR | hsa-miR-106a-5p | Gastric adenocarcinoma | MNDR-E-MI-03420 |
MNDR | hsa-miR-106a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-03421 |
MNDR | hsa-miR-106a-5p | Lung squamous cell carcinoma | MNDR-E-MI-03422 |
MNDR | hsa-miR-106a-5p | Carcinoma lung non-small-cell | MNDR-E-MI-03423 |
MNDR | hsa-miR-106a-5p | Lung adenocarcinoma | MNDR-E-MI-03424 |
MNDR | hsa-miR-106a-5p | Thyroid carcinoma | MNDR-E-MI-03425 |
MNDR | hsa-miR-106a-5p | Ovarian carcinoma | MNDR-E-MI-03426 |
MNDR | hsa-miR-106a-5p | Bladder urothelial carcinoma | MNDR-E-MI-03427 |
MNDR | hsa-miR-106a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-03428 |
MNDR | hsa-miR-106a-5p | Carcinoma renal cell | MNDR-E-MI-03429 |
MNDR | hsa-miR-106a-5p | Papillary renal cell carcinoma | MNDR-E-MI-03430 |
MNDR | hsa-miR-106a-5p | Clear cell renal cell cancer | MNDR-E-MI-03431 |
MNDR | hsa-miR-106a-5p | Biliary tract cancer | MNDR-E-MI-03432 |
MNDR | hsa-miR-106a-5p | Cholangiocarcinoma | MNDR-E-MI-03433 |
MNDR | hsa-miR-106a-5p | Esophageal cancer | MNDR-E-MI-03434 |
MNDR | hsa-miR-106a-5p | Lung small cell carcinoma | MNDR-E-MI-03435 |
MNDR | hsa-miR-106a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-03436 |
MNDR | hsa-miR-106a-5p | Testicular germ cell cancer | MNDR-E-MI-03437 |
MNDR | hsa-miR-106a-5p | T acute lymphoblastic leukemia | MNDR-E-MI-03438 |
MNDR | hsa-miR-106a-5p | Acute t cell leukemia | MNDR-E-MI-03439 |
MNDR | hsa-miR-106a-5p | Acute heart failure | MNDR-E-MI-03440 |
MNDR | hsa-miR-106a-5p | Aortic valve disease | MNDR-E-MI-03441 |
MNDR | hsa-miR-106a-5p | Adenoma | MNDR-E-MI-03442 |
MNDR | hsa-miR-106a-5p | Breast invasive carcinoma | MNDR-E-MI-03443 |
MNDR | hsa-miR-106a-5p | Hepatocellular carcinoma | MNDR-E-MI-03444 |
MNDR | hsa-miR-106a-5p | Embryonal cancer | MNDR-E-MI-03445 |
MNDR | hsa-miR-106a-5p | Familiar ovarian carcinoma | MNDR-E-MI-03446 |
MNDR | hsa-miR-106a-5p | B-cell lymphoma | MNDR-E-MI-03447 |
MNDR | hsa-miR-106a-5p | T-cell leukemia | MNDR-E-MI-03448 |
MNDR | hsa-miR-106a-5p | Neuroblastoma | MNDR-E-MI-03449 |
MNDR | hsa-miR-106a-5p | Burkitt lymphoma | MNDR-E-MI-03450 |
MNDR | hsa-miR-106a-5p | Psoriasis | MNDR-E-MI-03451 |
MNDR | hsa-miR-106a-5p | Acute myelocytic leukemia | MNDR-E-MI-03452 |
MNDR | hsa-miR-106a-5p | Colorectal cancer | MNDR-E-MI-03453 |
MNDR | hsa-miR-106a-5p | Multiple myeloma | MNDR-E-MI-03454 |
MNDR | hsa-miR-106a-5p | Ependymoma | MNDR-E-MI-03455 |
MNDR | hsa-miR-106a-5p | Prostatic neoplasms | MNDR-E-MI-03456 |
MNDR | hsa-miR-106a-5p | Pseudorabies | MNDR-E-MI-03457 |
MNDR | hsa-miR-106a-5p | Hypersomnolence idiopathic | MNDR-E-MI-03458 |
MNDR | hsa-miR-106a-5p | Arsenic poisoning | MNDR-E-MI-03459 |
MNDR | hsa-miR-106a-5p | Stroke lacunar | MNDR-E-MI-03460 |
MNDR | hsa-miR-106a-5p | Duke C | MNDR-E-MI-03461 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABHD2 | Homo sapiens | RR00026071 |
TOP